113 related articles for article (PubMed ID: 23382090)
1. Reply to: Letter to the editor "Impact of the CYP2C19*17 polymorphism on the pharmacokinetics and pharmacodynamics of proton pump inhibitors".
Jiang F; Shin JG
J Clin Pharmacol; 2013 Mar; 53(3):360. PubMed ID: 23382090
[No Abstract] [Full Text] [Related]
2. Impact of the CYP2C19*17 polymorphism on the pharmacokinetics and pharmacodynamics of proton pump inhibitors.
Mazer-Amirshahi M; van den Anker J
J Clin Pharmacol; 2013 Mar; 53(3):359. PubMed ID: 23381740
[No Abstract] [Full Text] [Related]
3. Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
Cho H; Choi MK; Cho DY; Yeo CW; Jeong HE; Shon JH; Lee JY; Shin JS; Cho M; Kim DY; Shin JG
J Clin Pharmacol; 2012 Jul; 52(7):976-84. PubMed ID: 21593280
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of the new proton pump inhibitor ilaprazole in Chinese healthy subjects in relation to CYP3A5 and CYP2C19 genotypes.
Li Y; Zhang W; Guo D; Zhou G; Zhou H; Xiao Z
Clin Chim Acta; 2008 May; 391(1-2):60-7. PubMed ID: 18319058
[TBL] [Abstract][Full Text] [Related]
5. CYP2C19 genotypes in the pharmacokinetics/pharmacodynamics of proton pump inhibitor-based therapy of Helicobacter pylori infection.
Yang JC; Lin CJ
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):29-41. PubMed ID: 19968574
[TBL] [Abstract][Full Text] [Related]
6. Review article: relationship between the metabolism and efficacy of proton pump inhibitors--focus on rabeprazole.
Horn J
Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():11-9. PubMed ID: 15496214
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphism of CYP2C19 & therapeutic response to proton pump inhibitors.
Chaudhry AS; Kochhar R; Kohli KK
Indian J Med Res; 2008 Jun; 127(6):521-30. PubMed ID: 18765869
[TBL] [Abstract][Full Text] [Related]
8. Impact of CYP2C19 polymorphisms on the clinical action of proton pump inhibitors (PPIs).
Klotz U
Eur J Clin Pharmacol; 2009 Jan; 65(1):1-2. PubMed ID: 18958459
[No Abstract] [Full Text] [Related]
9. [Dosaging of proton pumps inhibitors].
Brørs O
Tidsskr Nor Laegeforen; 2006 Sep; 126(18):2397-9. PubMed ID: 16998554
[No Abstract] [Full Text] [Related]
10. Metabolic disposition of pantoprazole, a proton pump inhibitor, in relation to S-mephenytoin 4'-hydroxylation phenotype and genotype.
Tanaka M; Ohkubo T; Otani K; Suzuki A; Kaneko S; Sugawara K; Ryokawa Y; Hakusui H; Yamamori S; Ishizaki T
Clin Pharmacol Ther; 1997 Dec; 62(6):619-28. PubMed ID: 9433390
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic interactions between omeprazole/pantoprazole and clarithromycin in health volunteers.
Calabresi L; Pazzucconi F; Ferrara S; Di Paolo A; Tacca MD; Sirtori C
Pharmacol Res; 2004 May; 49(5):493-9. PubMed ID: 14998561
[TBL] [Abstract][Full Text] [Related]
12. Recurrent anaphylaxis linked to pantoprazole.
Kollmeier AP; Eddleston J; Zuraw BL; Christiansen SC
J Allergy Clin Immunol; 2004 Oct; 114(4):975-7. PubMed ID: 15480345
[No Abstract] [Full Text] [Related]
13. Update on the pharmacogenomics of proton pump inhibitors.
Hagymási K; Müllner K; Herszényi L; Tulassay Z
Pharmacogenomics; 2011 Jun; 12(6):873-88. PubMed ID: 21692617
[TBL] [Abstract][Full Text] [Related]
14. [Recent topics on important drugs for H. pylori eradication: Rabeprazole].
Sugimoto M; Furuta T; Nakmura A; Shirai N
Nihon Rinsho; 2005 Nov; 63 Suppl 11():350-3. PubMed ID: 16363558
[No Abstract] [Full Text] [Related]
15. Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.
Frelinger AL; Bhatt DL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Lampa M; Brooks JK; Barnard MR; Michelson AD
J Am Coll Cardiol; 2013 Feb; 61(8):872-9. PubMed ID: 23333143
[TBL] [Abstract][Full Text] [Related]
16. Rabeprazole experience in Korea; focus on CYP2C19 polymorphism.
Park SH
J Gastroenterol Hepatol; 2005 Dec; 20 Suppl():S20-1. PubMed ID: 16359345
[No Abstract] [Full Text] [Related]
17. Effect of CYP2C19 and MDR1 polymorphisms on cure rate in patients with acid-related disorders with Helicobacter pylori infection.
Gawrońska-Szklarz B; Wrześniewska J; Starzyńska T; Pawlik A; Safranow K; Ferenc K; Droździk M
Eur J Clin Pharmacol; 2005 Jul; 61(5-6):375-9. PubMed ID: 15976989
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomics of proton pump inhibitors.
Furuta T; Shirai N; Sugimoto M; Ohashi K; Ishizaki T
Pharmacogenomics; 2004 Mar; 5(2):181-202. PubMed ID: 15016609
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
Andersson T
Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
[TBL] [Abstract][Full Text] [Related]
20. [Cytochrome-P-4502C19 gene polymorphism and Helicobacter pylori infection treatment].
Maev IV; Oganesian TS; Momynaliev KT; Kucheriavyĭ IuA; Belyĭ PA
Eksp Klin Gastroenterol; 2008; (3):78-85. PubMed ID: 19145886
[No Abstract] [Full Text] [Related]
[Next] [New Search]
